IXICO Plc (LON:IXI) has signed a new contract, worth US$690,000 over a two and a half year term, with an unnamed customer for its technology enabled imaging services.
The AIM-listed digital technologies company focused on neuroscience said the contract is for a Phase II clinical trial evaluating the safety and tolerability of a novel treatment for patients with Huntington's disease.
READ: IXICO to work on Huntington's disease trial for US biopharma
As part of the study, IXICO will use its TrialTracker™ digital platform and scientific services to provide a battery of advanced MRI imaging techniques and clinical trial endpoints.
Giulio Cerroni, IXICO’s CEO, commented: “This new contract further demonstrates the value our customers see in IXICO's deep neurological disease expertise combined with our proprietary digital technologies in providing compliant data standardisation, collection and analysis."